Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Cancer Immunology, Immunotherapy
Erschienen in: Cancer Immunology, Immunotherapy 2/2011

01.02.2011 | Review

Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model

verfasst von: Wim Maes, Stefaan W. Van Gool

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Nearly twenty years of experimental immunotherapy for malignant glioma yielded important insights in the mechanisms governing glioma immunology. Still considered promising, it is clear that immunotherapy does not on its own represent the magic bullet in glioma therapy. In this review, we summarize the major immunotherapeutic achievements in the mouse GL261 glioma model, which has emerged as the gold standard syngeneic model for experimental glioma therapy. Gene therapy, monoclonal antibody treatment, cytokine therapy, cell transfer strategies and dendritic cell therapy were hereby considered. Apart from the considerable progress made in understanding glioma immunology in this model, we also addressed its most pertinent issues and shortcomings. Despite these, the GL261 model will remain indispensable in glioma research since it is a fast, highly reproducible and easy-to-establish model system.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109CrossRefPubMed
2.
Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4(4):278–299PubMed
3.
Nieder C, Grosu AL, Molls M (2000) A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26(6):397–409CrossRefPubMed
4.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoom MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352:987–996CrossRef
5.
Aboody KS, Najbauer J, Danks MK (2008) Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 15(10):739–752CrossRefPubMed
6.
Aghi M, Chiocca EA (2006) Gene therapy for glioblastoma. Neurosurg Focus 20(4):E18PubMed
7.
8.
Reardon DA, Rich JN, Friedman HS, Bigner DD (2006) Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24(8):1253–1265CrossRefPubMed
9.
Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE et al (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85(2):133–148CrossRefPubMed
10.
Fomchenko EI, Holland EC (2006) Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 12(18):5288–5297CrossRefPubMed
11.
Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, Gage FH et al (2009) Development of a novel mouse glioma model using lentiviral vectors. Nat Med 15(1):110–116CrossRefPubMed
12.
Ausman JI, Shapiro WR, Rall DP (1970) Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 30(9):2394–2400PubMed
13.
Zimmerman HM, Arnold H (1941) Experimental brain tumors. I. Tumors produced with methylcholanthrene. Cancer Res 1:919–938
14.
Szatmari T, Lumniczky K, Desaknai S, Trajcevski S, Hidvegi EJ, Hamada H et al (2006) Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 97(6):546–553CrossRefPubMed
15.
Daga A, Orengo AM, Gangemi RM, Marubbi D, Perera M, Comes A et al (2007) Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int J Cancer 121(8):1756–1763CrossRefPubMed
16.
Segal BM, Glass DD, Shevach EM (2002) Cutting edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol 168(1):1–4PubMed
17.
Iizuka Y, Kojima H, Kobata T, Kawase T, Kawakami Y, Toda M (2006) Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine. Int J Cancer 118(4):942–949CrossRefPubMed
18.
Paul AK, Ciesielski MJ, Sajjad M, Wang X, Ferrone S, Abdel-Nabi H et al (2009) Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting. J Neurooncol 94(1):21–30CrossRefPubMed
19.
Ciesielski MJ, Kozbor D, Castanaro CA, Barone TA, Fenstermaker RA (2008) Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol Immunother 57(12):1827–1835CrossRefPubMed
20.
Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E, Toonen LW et al (2008) Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer 122(8):1794–1802CrossRefPubMed
21.
Maes W, Deroose C, Reumers V, Krylyshkina O, Gijsbers R, Baekelandt V et al (2009) In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma. J Neurooncol 91(2):127–139CrossRefPubMed
22.
Saris SC, Spiess P, Lieberman DM, Lin S, Walbridge S, Oldfield EH (1992) Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 76(3):513–519CrossRefPubMed
23.
Plautz GE, Touhalisky JE, Shu S (1997) Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 178(2):101–107CrossRefPubMed
24.
Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R et al (2001) Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 61(5):2031–2037PubMed
25.
Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60(19):5514–5521PubMed
26.
Kjaergaard J, Wang LX, Kuriyama H, Shu S, Plautz GE (2005) Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg 103(1):156–164CrossRefPubMed
27.
Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE et al (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13(7):2158–2167CrossRefPubMed
28.
El Andaloussi A, Han Y, Lesniak MS (2006) Prolongation of survival following depletion of CD4+ CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 105(3):430–437CrossRefPubMed
29.
Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL et al (2009) DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol 11(5):529–542CrossRefPubMed
30.
Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G et al (2009) Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 15(21):6551–6559CrossRefPubMed
31.
Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5(4):296–306CrossRefPubMed
32.
33.
Ni HT, Spellman SR, Jean WC, Hall WA, Low WC (2001) Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51(1):1–9CrossRefPubMed
34.
Aoki H, Mizuno M, Natsume A, Tsugawa T, Tsujimura K, Takahashi T et al (2001) Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50(9):463–468CrossRefPubMed
35.
Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M (2002) A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22(2A):613–621PubMed
36.
Saito R, Mizuno M, Nakahara N, Tsuno T, Kumabe T, Yoshimoto T et al (2004) Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma. Int J Cancer 111(5):777–782CrossRefPubMed
37.
Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K (2004) Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther 11(21):1551–1558CrossRefPubMed
38.
Kuwashima N, Nishimura F, Eguchi J, Sato H, Hatano M, Tsugawa T et al (2005) Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol 175(4):2730–2740PubMed
39.
Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B et al (2006) Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 66(21):10247–10252CrossRefPubMed
40.
Pellegatta S, Poliani PL, Corno D, Grisoli M, Cusimano M, Ubiali F et al (2006) Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res 28(5):527–531CrossRefPubMed
41.
Jiang XB, Lu XL, Hu P, Liu RE (2009) Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine 27(44):6210–6216CrossRefPubMed
42.
Prins RM, Odesa SK, Liau LM (2003) Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 63(23):8487–8491PubMed
43.
Ciesielski MJ, Apfel L, Barone TA, Castro CA, Weiss TC, Fenstermaker RA (2006) Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 55(12):1491–1503CrossRefPubMed
44.
Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A et al (2010) Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother 59(8):1211–1221CrossRefPubMed
45.
Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER et al (2009) Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells—significant roles of CXCL10. Cancer Res 69(4):1587–1595CrossRefPubMed
46.
Lichtor T, Glick RP, Kim TS, Hand R, Cohen EP (1995) Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83(6):1038–1044CrossRefPubMed
47.
Glick RP, Lichtor T, Panchal R, Mahendra A, Cohen EP (2003) Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors. J Neurooncol 64(1–2):139–146PubMed
48.
Spagnolo A, Glick RP, Lin H, Cohen EP, Feinstein DL, Lichtor T (2007) Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts. J Neurosurg 106(2):299–305CrossRefPubMed
49.
Herrlinger U, Kramm CM, Johnston KM, Louis DN, Finkelstein D, Reznikoff G et al (1997) Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 4(6):345–352PubMed
50.
Herrlinger U, Jacobs A, Quinones A, Woiciechowsky C, Sena-Esteves M, Rainov NG et al (2000) Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Hum Gene Ther 11(10):1429–1438CrossRefPubMed
51.
Yu JS, Burwick JA, Dranoff G, Breakefield XO (1997) Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 8(9):1065–1072CrossRefPubMed
52.
Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee T, Kawashima N et al (2006) The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res 12(15):4730–4737CrossRefPubMed
53.
Natsume A, Mizuno M, Ryuke Y, Yoshida J (1999) Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 6(9):1626–1633CrossRefPubMed
54.
Natsume A, Tsujimura K, Mizuno M, Takahashi T, Yoshida J (2000) IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 47(2):117–124CrossRefPubMed
55.
Blaszczyk-Thurin M, Ertl IO, Ertl HC (2002) An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53. Scand J Immunol 56(4):361–375CrossRefPubMed
56.
Wu A, Oh S, Ericson K, Demorest ZL, Vengco I, Gharagozlou S (2007) Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma. Cancer Gene Ther 14(6):550–560CrossRefPubMed
57.
Sonabend AM, Velicu S, Ulasov IV, Han Y, Tyler B, Brem H et al (2008) A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. Anticancer Drugs 19(2):133–142CrossRefPubMed
58.
Vetter M, Hofer MJ, Roth E, Pircher HP, Pagenstecher A (2009) Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma. J Neuropathol Exp Neurol 68(5):525–534CrossRefPubMed
59.
Enderlin M, Kleinmann EV, Struyf S, Buracchi C, Vecchi A, Kinscherf R et al (2009) TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther 16(2):149–160CrossRefPubMed
60.
El Andaloussi A, Sonabend AM, Han Y, Lesniak MS (2006) Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 54(6):526–535CrossRefPubMed
61.
Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S et al (2008) TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 181(10):6720–6729PubMed
62.
Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J et al (2007) Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 5:10CrossRefPubMed
63.
Gomez GG, Kruse CA (2006) Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 10(a):133–146PubMed
64.
Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF et al (2008) Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 180(4):2089–2098PubMed
65.
Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B (2009) Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia 57(13):1458–1467CrossRefPubMed
66.
De Vleeschouwer S, Rapp M, Sorg RV, Steiger HJ, Stummer W, Van Gool S et al (2006) Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery 59(5):988–999PubMed
67.
Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M et al (1999) Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 45(2):141–157CrossRefPubMed
68.
June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117(6):1466–1476CrossRefPubMed
69.
Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE et al (1995) Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′)2—a preliminary report. J Neurooncol 24(1):109–122CrossRefPubMed
70.
Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD (2004) Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther 4(9):1453–1471CrossRefPubMed
71.
Parajuli P, Sloan AE (2004) Dendritic cell-based immunotherapy of malignant gliomas. Cancer Invest 22(3):405–416CrossRefPubMed
72.
Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S et al (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68(14):5955–5964CrossRefPubMed
73.
De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J et al (2008) Clinical experience of postoperative adjuvant dendritic cell-based immunotherapy in a large group of patients with relapsed glioblastoma multiforme. Clin Cancer Res 14(10):3098–3104CrossRefPubMed
74.
Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G et al (2010) Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 99(2):261–272CrossRefPubMed
75.
Rainov NG, Ren H (2003) Gene therapy for human malignant brain tumors. Cancer J 9(3):180–188CrossRefPubMed
76.
Andersen MH, Sorensen RB, Schrama D, Svane IM, Becker JC, Thor SP (2008) Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 57(11):1735–1743CrossRefPubMed
77.
Kim TG, Kim CH, Park JS, Park SD, Kim CK, Chung DS et al (2010) Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol 17(1):143–153CrossRefPubMed
78.
Liu G, Black KL, Yu JS (2006) Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines 5(2):233–247CrossRefPubMed
79.
Schlegel PG, Eyrich M, Kramm C, Van Gool S (2010) Tumor vaccination for high-grade glioma. Pediatr Blood Cancer 55(7):1437CrossRefPubMed
80.
Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F et al (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56(5):641–648CrossRefPubMed
81.
Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP (2002) Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 9(5):464–469CrossRefPubMed
82.
Herrlinger U, Aulwurm S, Strik H, Weit S, Naumann U, Weller M (2004) MIP-1alpha antagonizes the effect of a GM-CSF-enhanced subcutaneous vaccine in a mouse glioma model. J Neurooncol 66(1–2):147–154CrossRefPubMed
83.
Smith KE, Janelidze S, Visse E, Badn W, Salford L, Siesjo P et al (2007) Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma. Int J Cancer 120(1):75–80CrossRefPubMed
84.
Smith KE, Fritzell S, Badn W, Eberstal S, Janelidze S, Visse E (2009) Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells. Int J Cancer 124(3):630–637CrossRefPubMed
Metadaten
Titel
Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model
verfasst von
Wim Maes
Stefaan W. Van Gool
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 2/2011
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-010-0946-6

Weitere Artikel der Ausgabe 2/2011

Cancer Immunology, Immunotherapy 2/2011 Zur Ausgabe

Original Article

Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer

Original Article

Natural antibodies against nerve growth factor inhibit in vitro prostate cancer cell metastasis

Original Article

Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors

Original Article

IL-21-treated naive CD45RA+ CD8+ T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype

Original Article

CDR2 antigen and Yo antibodies

Original Article

Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise